Evidence map›Paper›PMID 38946472›Full record

ArticleDisease models & mechanisms2024

Functional distinction in oncogenic Ras variant activity in Caenorhabditis elegans.

Haimeng Lyu, Helen M Chamberlin

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Haimeng LyuDepartment of Molecular Genetics, Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA.
Helen M ChamberlinDepartment of Molecular Genetics, Ohio State University, 484 West 12th Avenue, Columbus, OH 43210, USA.ORCID 0000-0001-7203-2691

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Ann E. Rougvie · 2012 to 2026
$7.5M
Genetic and genomic tools for C. briggsae researchR21OD030067 · OD · OHIO STATE UNIVERSITY · PI ANDERSEN, ERIK CHRISTIAN, CHAMBERLIN, HELEN M · 2022 to 2023
$431k
NCI NIH HHS P30 CA016058NIH HHS P40 OD010440NIH HHS R21 OD030067NIH HHS R21OD030067OSU: The Ohio State University
6 · The paper itself

Abstract

Ras genes are important oncogenes that are frequently mutated in cancer. Human oncogenic variants exhibit functional distinctions in terms of their representation in different cancer types, impact on cellular targets and sensitivity to pharmacological treatments. However, how these distinct variants influence and respond to the cellular networks in which they are embedded is poorly understood. To identify novel participants in the complex interplay between Ras genotype and cell interaction networks in vivo, we have developed and tested an experimental framework using a simple vulva-development assay in the nematode C. elegans. Using this system, we evaluated a set of Ras oncogenic substitution changes at G12, G13 and Q61. We found that these variants fall into distinct groups based on phenotypic differences, sensitivity to gene dosage and inhibition of the downstream kinase MEK and their response to genetic modulators that influence Ras activity in a non-autonomous manner. Together, our results demonstrated that oncogenic C. elegans Ras variants exhibit clear distinctions in how they interface with the vulva-development network and showed that extracellular modulators yield variant-restricted effects in vivo.

Indexed as

Caenorhabditis elegansras ProteinsVulvaAnimalsCaenorhabditis elegans ProteinsFemaleHumansMutationOncogenesPhenotypeCaenorhabditis elegans Proteinsras ProteinsC. elegans vulva developmentOncogenic Ras variantsRas/MEK signaling pathway

Identifiers

PMID38946472
PMCPMC11340813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.